Clearside Biomedical transitions all employees to consulting roles

“Given the current unpredictable economic environment and challenging fundraising conditions in the biopharmaceutical industry, we are taking the necessary next steps to evaluate strategic alternatives for the Company. In order to facilitate this process and conserve cash, while continuing our support of the Company’s SCS Microinjector licensees, all Clearside employees, including the CEO, CFO, and CMO, will transition into consulting roles with the Company this week. In addition, we will pause all internal research and development programs during this process,” said CEO George Lasezkay.